Reumatologia Clinica最新文献

筛选
英文 中文
Do psychosocial factors predict disease severity in fibromyalgia syndrome? 心理社会因素能预测纤维肌痛综合征的病情严重程度吗?
IF 1.2
Reumatologia Clinica Pub Date : 2025-05-01 DOI: 10.1016/j.reuma.2025.501893
Hasan Huseyin Gokpinar , Cihan Caner Aksoy , Muhammed Fatih Ozdemir , İsmail Saraçoğlu
{"title":"Do psychosocial factors predict disease severity in fibromyalgia syndrome?","authors":"Hasan Huseyin Gokpinar ,&nbsp;Cihan Caner Aksoy ,&nbsp;Muhammed Fatih Ozdemir ,&nbsp;İsmail Saraçoğlu","doi":"10.1016/j.reuma.2025.501893","DOIUrl":"10.1016/j.reuma.2025.501893","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this study was to examine anxiety, depression, pain centralization, and pain catastrophization in patients with fibromyalgia syndrome (FMS) and evaluate whether these factors are predictors of disease severity in FMS.</div></div><div><h3>Patient and methods</h3><div>Depression was assessed with the Beck Depression Inventory (BDI), anxiety with the Beck Anxiety Inventory (BAI), pain centralization with the Centrality of Pain Scale (COPS), pain catastrophization with the Pain Catastrophizing Scale (PCS), and FMS severity with the Fibromyalgia Impact Questionnaire (FIQ). Two separate hierarchical linear regression analyses were performed to determine whether there was a significant association between disease severity and the assessed psychosocial factors.</div></div><div><h3>Results</h3><div>The study was completed with a total of 48 FMS patients (mean age 49.54<!--> <!-->±<!--> <!-->8.28 years). FIQ score was moderately correlated with COPS score (<em>r</em><sub>Spearman</sub> <!-->=<!--> <!-->0.670, <em>p</em> <!-->&lt;<!--> <!-->0.001) and PCS score (<em>r</em><sub>Spearman</sub> <!-->=<!--> <!-->0.663, <em>p</em> <!-->&lt;<!--> <!-->0.001). In the logistic regression model, COPS and PCS scores were significant predictors of FIQ score. The predictive variables explained 43.7% of the variation in FIQ score.</div></div><div><h3>Conclusion</h3><div>This study showed that pain centralization and catastrophization can be considered indicators of disease severity in FMS. The results suggest that routine assessment of pain centralization and pain catastrophizing behaviors in individuals with FMS is needed and that cognitive behavioral therapy approaches may be beneficial in reducing disease severity.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501893"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RS3PE post-COVID: nueva evidencia de enfermedades autoinmunes tras la infección por SARS-CoV-2 新冠病毒后的RS3PE: SARS-CoV-2感染后自身免疫性疾病的新证据
IF 1.2
Reumatologia Clinica Pub Date : 2025-05-01 DOI: 10.1016/j.reuma.2025.501898
Begoña Miquel Veyrat, José Chordá Ribelles, Mar Gómez Martí
{"title":"RS3PE post-COVID: nueva evidencia de enfermedades autoinmunes tras la infección por SARS-CoV-2","authors":"Begoña Miquel Veyrat,&nbsp;José Chordá Ribelles,&nbsp;Mar Gómez Martí","doi":"10.1016/j.reuma.2025.501898","DOIUrl":"10.1016/j.reuma.2025.501898","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501898"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osteomalacia hipofosfatémica secundaria a tumor mesenquimal 继发性低磷酸骨髓瘤至间充质瘤
IF 1.2
Reumatologia Clinica Pub Date : 2025-05-01 DOI: 10.1016/j.reuma.2025.501897
Aurora González Murcia , Isabel Valencia Ramírez , Teresa Catalina Plaza Aguado , José Antonio González Ferrández
{"title":"Osteomalacia hipofosfatémica secundaria a tumor mesenquimal","authors":"Aurora González Murcia ,&nbsp;Isabel Valencia Ramírez ,&nbsp;Teresa Catalina Plaza Aguado ,&nbsp;José Antonio González Ferrández","doi":"10.1016/j.reuma.2025.501897","DOIUrl":"10.1016/j.reuma.2025.501897","url":null,"abstract":"<div><div>We present the case of a 42-year-old male patient who is admitted for the study of axial and pelvic girdle pain, being diagnosed with hypophosphatemic osteomalacia secondary to a mesenchymal tumor after ruling out other causes of osteomalacia.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501897"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estudio del impacto de la inclusión de la valoración global del dolor y la capacidad funcional en la definición de remisión y su mantenimiento en la artritis reumatoide. Objetivos y metodología 研究将疼痛和功能的整体评估纳入缓解定义及其在类风湿关节炎中的维持的影响。目标和方法
IF 1.2
Reumatologia Clinica Pub Date : 2025-05-01 DOI: 10.1016/j.reuma.2025.501895
Alejandro Balsa , Daniel Seoane-Mato , Marta Domínguez-Álvaro , Mercedes Alperi , Virginia Ruiz-Esquide , Javier Bachiller-Corral , Federico Díaz-González , en representación del Grupo del estudio Remisión-AR
{"title":"Estudio del impacto de la inclusión de la valoración global del dolor y la capacidad funcional en la definición de remisión y su mantenimiento en la artritis reumatoide. Objetivos y metodología","authors":"Alejandro Balsa ,&nbsp;Daniel Seoane-Mato ,&nbsp;Marta Domínguez-Álvaro ,&nbsp;Mercedes Alperi ,&nbsp;Virginia Ruiz-Esquide ,&nbsp;Javier Bachiller-Corral ,&nbsp;Federico Díaz-González ,&nbsp;en representación del Grupo del estudio Remisión-AR","doi":"10.1016/j.reuma.2025.501895","DOIUrl":"10.1016/j.reuma.2025.501895","url":null,"abstract":"<div><h3>Background and objective</h3><div>The SUMAR project established a definition for remission that includes the patient's perspective (global assessment of pain and HAQ) in the definition of remission in rheumatoid arthritis (RA). This new definition needs to be assessed on clinical practice. The main objective of the RA-Remission study is to estimate the proportion of patients in sustained remission according to SUMAR definition through 2-year follow-up, among patients in SUMAR remission at baseline. This manuscript describes the objectives and methodology of the study.</div></div><div><h3>Materials and methods</h3><div>This is a longitudinal, prospective, observational and multicentre study, involving 10 centres. Patients with RA who have achieved clinical remission in accordance to their attending rheumatologist clinical judgement within the last 6 months will be included. Follow-up visits will take place at 3, 6, 12, 12, 18 and 24 months. Ultrasound assessment of the power Doppler (PD) signal for 30 joints and 6 tendon regions will be performed at each participating centre by an expert blinded to all other study findings. Definitions of remission according to SUMAR, PD and activity indices will be used. Sustained remission will be considered for each of the definitions when the patient in remission at the baseline visit maintains it during all follow-up visits. To estimate the proportion of patients maintaining remission at two years with an accuracy of at least 6%, 180 patients will need to be recruited.</div></div><div><h3>Discussion and conclusions</h3><div>The main strength of the design is the use of ultrasound assessment as the gold standard for assessing inflammatory activity.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501895"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ocular inflammatory manifestations in patients with rheumatoid arthritis 类风湿关节炎患者的眼部炎症表现
IF 1.2
Reumatologia Clinica Pub Date : 2025-05-01 DOI: 10.1016/j.reuma.2025.501891
Raul E. Ruiz-Lozano , Luis Arnaldo Prida-Espaillat , Reinaldo A. Moll-Auais , Eugenia M. Ramos-Dávila , Manuel E. Quiroga-Garza , Aaron Zhao , Ali Khodor , Amr Almobayed , David Vega-Morales , Alejandro Rodriguez-Garcia
{"title":"Ocular inflammatory manifestations in patients with rheumatoid arthritis","authors":"Raul E. Ruiz-Lozano ,&nbsp;Luis Arnaldo Prida-Espaillat ,&nbsp;Reinaldo A. Moll-Auais ,&nbsp;Eugenia M. Ramos-Dávila ,&nbsp;Manuel E. Quiroga-Garza ,&nbsp;Aaron Zhao ,&nbsp;Ali Khodor ,&nbsp;Amr Almobayed ,&nbsp;David Vega-Morales ,&nbsp;Alejandro Rodriguez-Garcia","doi":"10.1016/j.reuma.2025.501891","DOIUrl":"10.1016/j.reuma.2025.501891","url":null,"abstract":"<div><h3>Purpose</h3><div>This review emphasizes the significance of clinical findings, pathogenic mechanisms, diagnosis, management, and complications related to the ocular manifestations of rheumatoid arthritis, underscoring the need for interdisciplinary collaboration between rheumatologists and ophthalmologists.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was conducted using PubMed, Embase, Web of Science, and Google Scholar for all English-language articles published from inception to July 2024. The following search string was utilized: (“rheumatoid arthritis”) AND (“dry eye disease” OR “dry eye” OR “episcleritis” OR “scleritis” OR “peripheral ulcerative keratitis” OR “central corneal ulcer*” OR “paracentral corneal ulcer*” OR “ocular manifestations” OR “ocular involvement”). Letters to the editor, editorials, short communications, case reports, case series, review articles, and original articles were reviewed, along with relevant references from those publications.</div></div><div><h3>Results</h3><div>The most common ocular manifestations in patients with rheumatoid arthritis include keratoconjunctivitis sicca (dry eye disease), episcleritis, scleritis, peripheral ulcerative keratitis, and central and paracentral corneal ulceration. Ocular involvement can be the initial presentation of the disease and may correlate with disease activity. If left untreated, ocular inflammation in rheumatoid arthritis can lead to permanent vision loss.</div></div><div><h3>Conclusions</h3><div>The diverse ocular inflammatory manifestations in RA patients may indicate either the disease's initial presentation or the status of extra-articular activity. A multidisciplinary approach that includes rheumatologists and ophthalmologists is essential to prevent sight-threatening complications.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501891"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144262871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Some aspects of body thermoregulation, environmental temperature and vascular hypothesis in systemic sclerosis patients 系统性硬化症患者体温调节、环境温度及血管假说的若干方面
IF 1.2
Reumatologia Clinica Pub Date : 2025-05-01 DOI: 10.1016/j.reuma.2025.501894
Francisco Javier Olmedo Garzón
{"title":"Some aspects of body thermoregulation, environmental temperature and vascular hypothesis in systemic sclerosis patients","authors":"Francisco Javier Olmedo Garzón","doi":"10.1016/j.reuma.2025.501894","DOIUrl":"10.1016/j.reuma.2025.501894","url":null,"abstract":"<div><div>In line with vascular hypothesis of systemic sclerosis (SSc), it is proposed that visceral Raynaud's phenomenon (RP)/endothelial dysfunction causes severe oxygen supply/consumption imbalance in internal organs, leading to visceral ischemic failure in early SSc, especially with cold environmental temperature (Te) and severe RP. There would also be a decrease in body thermogenesis and a decrease in heat loss caused by chronic visceral ischemia and by systemic vasculopathy, respectively. At any given time, these disorders could produce low core temperature (Tc). Hence, SSc is proposed as a candidate cause of secondary hypothermia. It is suggested that SSc could be an adaptive response in cold Te to systemic endothelial damage with secondary chronic visceral ischemia/slow metabolism. This pathophysiological mechanism is proposed in early visceral failure, prognosis, SSc phenotype according to ethnicity, and other manifestations. The impact of Te and Tc on SSc warrants further investigations.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501894"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry ixekizumab在银屑病关节炎和轴性脊柱炎患者中的1年保留率:来自BIOBADASER注册的真实世界数据
IF 1.2
Reumatologia Clinica Pub Date : 2025-05-01 DOI: 10.1016/j.reuma.2025.501872
Clementina López-Medina , Lucía Otero-Varela , Fernando Sánchez-Alonso , Vega Jovaní , Lorena Expósito-Pérez , Sheila Melchor-Díaz , Yanira Pérez-Vera , Paula Pretel-Ruiz , Javier Manero , Antonio Mera-Varela , Lourdes Mateo , Dolores Ruiz-Montesino , José Andrés Lorenzo-Martín , Teresa Pedraz-Penalva , Isabel Castrejón
{"title":"One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry","authors":"Clementina López-Medina ,&nbsp;Lucía Otero-Varela ,&nbsp;Fernando Sánchez-Alonso ,&nbsp;Vega Jovaní ,&nbsp;Lorena Expósito-Pérez ,&nbsp;Sheila Melchor-Díaz ,&nbsp;Yanira Pérez-Vera ,&nbsp;Paula Pretel-Ruiz ,&nbsp;Javier Manero ,&nbsp;Antonio Mera-Varela ,&nbsp;Lourdes Mateo ,&nbsp;Dolores Ruiz-Montesino ,&nbsp;José Andrés Lorenzo-Martín ,&nbsp;Teresa Pedraz-Penalva ,&nbsp;Isabel Castrejón","doi":"10.1016/j.reuma.2025.501872","DOIUrl":"10.1016/j.reuma.2025.501872","url":null,"abstract":"<div><h3>Introduction</h3><div>Ixekizumab (IXE) is a selective interleukin 17A (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Limited real-world data are available on its retention rate and effectiveness. The objective of this study was to assess the one-year retention rate of IXE in a real-world cohort of patients with axSpA and PsA and to identify potential predictive factors for drug retention.</div></div><div><h3>Method</h3><div>Prospective and observational study derived from BIOBADASER 3.0, a multicenter registry of advanced therapies including patients who have ever received IXE for PsA or axSpA. The one-year retention rate of the treatment in both diseases was evaluated using Kaplan–Meier curves and multivariable Cox regressions.</div></div><div><h3>Results</h3><div>A total of 335 patients ever exposed to IXE were included (PsA<!--> <!-->=<!--> <!-->250; axSpA<!--> <!-->=<!--> <!-->85). IXE was used as first-line treatment only in 5.3% of patients, and after TNFi in 94.7% of patients. In axSpA and PsA, drug survival at 12 months was 69.5% (95% CI 64.0–74.3), slightly higher in PsA (71.3% (95% CI 65.0–75.6)) versus axSpA (63.8% (95% CI 51.5–73.7)). The multivariable Cox regression models showed that female sex and longer disease duration were factors associated with IXE withdrawal in the whole population, while concomitant use of methotrexate reduced the risk of discontinuation.</div></div><div><h3>Conclusions</h3><div>In this real-world study, IXE showed an acceptable retention rate in patients with PsA and axSpA after one year of follow-up. Female sex and longer disease duration were associated with risk of withdrawal.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501872"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lupus nephritis in Mexican patients: Response to intensive therapy 墨西哥狼疮性肾炎患者:对强化治疗的反应
IF 1.2
Reumatologia Clinica Pub Date : 2025-05-01 DOI: 10.1016/j.reuma.2025.501896
Georgina Aguilera Barragán-Pickens , David Herrera van-Oostdam , Fedra Irazoque-Palazuelos , Miguel Saavedra-Salinas , Sergio Cerpa-Cruz , Claudia Mendoza-Pinto , Luis Valdez , Enrique Cuevas Orta , Eva Santillán-Guerrero , Carlos Abud-Mendoza , LUNPOS GROUP
{"title":"Lupus nephritis in Mexican patients: Response to intensive therapy","authors":"Georgina Aguilera Barragán-Pickens ,&nbsp;David Herrera van-Oostdam ,&nbsp;Fedra Irazoque-Palazuelos ,&nbsp;Miguel Saavedra-Salinas ,&nbsp;Sergio Cerpa-Cruz ,&nbsp;Claudia Mendoza-Pinto ,&nbsp;Luis Valdez ,&nbsp;Enrique Cuevas Orta ,&nbsp;Eva Santillán-Guerrero ,&nbsp;Carlos Abud-Mendoza ,&nbsp;LUNPOS GROUP","doi":"10.1016/j.reuma.2025.501896","DOIUrl":"10.1016/j.reuma.2025.501896","url":null,"abstract":"<div><h3>Introduction</h3><div>lupus nephritis represents a challenge in treatment. In spite of intensive therapy, is common a sustained renal incomplete response.</div></div><div><h3>Objective</h3><div>To describe different responses to adequate/intensive treatment to lupus nephritis.</div></div><div><h3>Methods</h3><div>Observational retrospective study, including Mexican<!--> <!-->&gt;<!--> <!-->18 years old patients with lupus nephritis who visited tertiary rheumatology centers in several urban cities in Mexico. SLE was diagnosed according to 1997 ACR. The exclusion criteria were follow-up<!--> <!-->&lt;<!--> <!-->6 months and reduced GFR due to other comorbidities such as diabetes or other primary renal disease.</div></div><div><h3>Results</h3><div>We included 193 patients with a mean age of 34 years, 80% were women. Biopsy was available in 166 patients (86%): class IV in 42%, class III in 23%, the mean of activity and chronicity index were 6.4 and 2.6 respectively; class V represented 10.2%. The least frequent class was Class II (9%), and mixed classes (III or IV<!--> <!-->+<!--> <!-->V) accounted for 11%.</div><div>Cyclophosphamide (CYC) was used in 146 patients (76.6%), mycophenolate (MMF) in 144 and tacrolimus (TCR) in 28. In most cases, were used combination therapy.</div><div>Only 38 patients had a follow-up of less than 1 year; 16 (42%) had CR, 13 (34%) had NR, and 9 (23%) PR. 55% of patients with PR received a multitarget protocol, 75% of CR received the NIH protocol, and 61.5% of NR the NIH protocol.</div><div>Of patients followed up for more than a year (155), 35% had persistently inactive response, 24.5% were relapsing–remitting, 20% were chronically active, and 20% showed a mixed pattern.</div></div><div><h3>Conclusions</h3><div>Prevalence of persistent or intermittent activity patterns was high (64.5%). Most Mexican rheumatologists switched to more intensive treatment, adding a second or third drug.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501896"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144262870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on: “Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: Data from the BIOBADAGUAY registry” 评论:“生物和合成靶向治疗在免疫介导性疾病患者中的安全性:来自BIOBADAGUAY注册的数据”
IF 1.2
Reumatologia Clinica Pub Date : 2025-04-01 DOI: 10.1016/j.reuma.2025.501871
Sarah Aijaz , Raveen Muzaffer
{"title":"Comment on: “Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: Data from the BIOBADAGUAY registry”","authors":"Sarah Aijaz ,&nbsp;Raveen Muzaffer","doi":"10.1016/j.reuma.2025.501871","DOIUrl":"10.1016/j.reuma.2025.501871","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501871"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel imaging findings of masticatory muscle edema in dermatomyositis associated with ovarian cancer: A case report 卵巢癌皮肌炎伴咀嚼肌水肿的新影像学表现:1例报告
IF 1.2
Reumatologia Clinica Pub Date : 2025-04-01 DOI: 10.1016/j.reuma.2025.501857
Leonardo F. Freitas , Márcio Luís Duarte , Kevin J. Abrams
{"title":"Novel imaging findings of masticatory muscle edema in dermatomyositis associated with ovarian cancer: A case report","authors":"Leonardo F. Freitas ,&nbsp;Márcio Luís Duarte ,&nbsp;Kevin J. Abrams","doi":"10.1016/j.reuma.2025.501857","DOIUrl":"10.1016/j.reuma.2025.501857","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501857"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信